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Serotonin or 5-hydroxytryptamine (5-HT) is primarily involved in the regulation of learning and memory.
Pathological changes in metabolism or functional imbalance of 5-HT has been associated with Alzheimer's disease
(AD). The hypothesis tested is that in peripheral blood, markers of the serotonergic pathway can be used as a
diagnostic tool for AD. The current study measured the relative expression of 5-HT receptors (5-HTR2A and 5-
HTR3A) as well as the 5-HT catalytic enzyme, Monoamine oxidase A (MAO-A) mRNA in Peripheral Blood
Mononuclear Cells (PBMCs) of patients with late-onset Alzheimer's disease (LOAD) and age-matched controls. 5-
HTR2A, 5-HTR3A, and MAO-A mRNA expressions were examined in PBMCs of 30 patients with LOAD and 30
control individuals. Real-time quantitative PCR was used to measure mRNA expression. The dementia status of
patients in this study was assessed using a Mini-Mental State Examination (MMSE). Mean data of relative mRNA
expression of 5-HTR2A, 5-HTR3A and MAO-A were significantly lower in PBMCs of patients with LOAD compared
with controls. Based on the down-regulation of serotonergic markers in PBMCs, our findings may be another claim
to the systemic nature of LOAD. The role of peripheral serotonergic downregulation, in the pathogenesis of AD,
needs to be further studied. Given the extremely convenient access to PBMCs, these molecular events may
represent more complete dimensions of AD neuropathophysiology or possibly lead to a new direction in studies
focused on blood-based markers.1. Introduction
Alzheimer's disease (AD) is the most common type of dementia,
which is caused by the demise of neurons in the aged brain [1]. It is
progressive and causes patients to be deprived of memory, communica-
tion skills and the ability to live independently [2, 3]. The high preva-
lence of AD (10% of people over the age of 65), and its heavy social and
economic burden have created major challenges to public health in the
21st century [2, 4, 5]. Previous studies have shown that beta-amyloid
(Aβ) and tau proteins contribute to the clinical development of the dis-
ease [1, 6]. In sporadic AD (also known as late-onset AD, LOAD), the age
at which the disease starts is over 65 years old and accounts for more than
95% of cases of AD. LOAD is considered as a multifactorial (or complex)
disease, and several environmental and genetic factors contribute to its
pathogenesis [7, 8]. It is estimated that genetic abnormalities occur in
70% of LOAD patients [9].6 June 2020; Accepted 11 Augu
vier Ltd. This is an open access arThere are several hypotheses regarding the complex pathogenesis of
AD, in which many of the various factors are interconnected. However,
none of the hypotheses has been able to recapitulate all of the patho-
logical aspects of AD and further studies are warranted [8]. 5-HT is a
biogenic monoamine that acts as a neurotransmitter, neuromodulator
and also a peripheral neurocrine hormone [10, 11]. 5-HT is involved in
regulating learning and memory processes in adulthood. Pathological
changes in the metabolism of 5-HT, or the imbalance in the transmission
of serotonergic messages, have been associated with the etiology of a
variety of pathophysiological conditions in the brain including AD [12].
In the brain of AD patients, the reduction in the number of serotonergic
neurons in the raphe nucleus, as well as the reduction of 5-HT and its
metabolites in post-mortem tissue has been observed [13, 14]. Several
5-HT receptors including 5-HT2A, 5-HT2C and 5-HT4 modulate amyloid
precursor protein (APP) processing which is necessary for Aβ formation.
Several reports also emphasized the beneficial effects of 5-HT6R receptorst 2020
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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that the serotonergic system may be involved in tau hyper-
phosphorylation, which is another hallmark of AD [17].
Monoamine oxidase-A (MAO-A) is an enzyme that acts as a 5-HT
degradation catalyst (oxidative deamination) and plays an important
role in regulating intracellular levels of the neurotransmitter [18, 19].
Studies have shown that MAOs are associated with multiple neurological
and psychiatric disorders, including AD [20]. It has also been noted that
in different regions of the brain of AD patients, the level of activity of
MAO-A and its expression is up-regulated [21]. Therefore, it has been
thought that MAO inhibitors increase amine neurotransmitters, decrease
ROS and have neuroprotective effects [22]. Although AD was commonly
considered as a brain disorder, it has now become clear that AD is a
systemic disease that also affects peripheral tissues outside of the central
nervous system [23]. In confirmation of this concept, a number of studies
have shown that in 80% of cases, blood- and brain-derived cells have
similar transcriptome [24]. In this regard, blood cells and several brain
tissues have remarkable similarity for gene expression that encodes
neurotransmitter receptors [11].
Based on previous findings that suggest both 5-HT and MAO systemic
disorders play a role in the pathophysiology of AD, the present study
aimed to determine the relative expression patterns of related genes in
Peripheral Blood Mononuclear Cells (PBMCs) in AD patients and
compare them with control individuals. The goal was to establish if pe-
ripheral markers can be developed to aid in the clinical diagnosis of AD.
We examined the expression of 5-HTR2A, 5-HTR3A and MAO-A mRNA
extracted from PBMCs simultaneously. It was hypothesized that there
would be a significant difference between the mean relative expression of
selected genes in the control and LOAD groups. In addition, we examined
the relationship between the expression levels of 5-HT receptors (5-
HTR2A, 5-HTR3A) and MAO with demographic characteristics of Alz-
heimer's patients. This part of the study hypothesised that there is a
correlation between age, duration of AD and MMSE total score with the
relative expression of 5HTR2A, 5HTR3A and MAO genes.
2. Materials and methods
2.1. Study population
Study participants were recruited from a residential aged-care fa-
cility located in Mehriz County, Yazd, Iran. The population of the study
was the residents 65 years or older. Thirty participants (15 females, 15
males) were recruited for each of the control and LOAD groups. The
participants were evaluated by a geriatrician dispatched from the
memory clinic of Hazrat-Rasoul-Akram Hospital (affiliated with Iran
University of Medical Sciences) to determine the memory status of the
study participants. The patients were diagnosed by the Diagnostic and
Statistical Manual of the American Psychiatric Association (DSM-IV). All
patients with LOAD underwent conventional neuropsychiatric testing.
Mini-Mental State Examination (MMSE) was performed for all the par-
ticipants [25, 26, 27]. The control group (non-Alzheimer's volunteer)
were selected from a cohort of people aged 65 years and over in the
same residential center and two daycare centers located in the sameTable 1. Demographic and clinical characteristics of participants.
LOAD patients (n ¼ 30)
Male/female, n 15/15
Age (years), mean  SD 88.7  6.4
MMSE total score, mean  SD 9.1  3.1
Age of disease onset, mean  SD 78.9  8.8
Duration of illness (years), mean  SD 9.8  6.5
SD, Standard Deviation; LOAD, Late-onset Alzheimer's disease; MMSE, Mini-Mental
includes the categories of severe (9 or less), moderate (10–18 points), mild (19–23 p
2
city. Detailed medical information was obtained from the records of the
residential aged-care facility. Subsequently, all individuals or their
caregivers completed a questionnaire that asked for personal and family
history of AD, medical pedigree, demographic characteristics, labora-
tory test results, and medication use. Subjects with AD and less than 65
years of age, familial AD, non-Alzheimer's dementia (secondary to other
central nervous system or systemic conditions), psychotic disorders and
patients under supportive drug therapy in the treatment of AD were
excluded. Written informed consent was obtained from all participants
or their primary caregivers before the enrolment into the study. The
study protocol was approved by the ethical committee of the National
Institute of Genetic Engineering and Biotechnology Research (NIGEB).
The demographic characteristics of the study groups are summarized in
Table 1.2.2. Mononuclear cell separation, RNA isolation, and reverse transcription
Complete blood samples were collected in 5 ml volume from all
participants by phlebotomy from the antecubital vein. The samples were
then poured into tubes containing 0.5 ml of ethylenediaminetetraacetic
acid (EDTA) with anticoagulant activity. PBMCs were isolated from the
rest of the blood components using a gradient density centrifuge tech-
nique using Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). RNA
extraction from PBMCs was performed by the High Pure RNA Isolation
Kit (Roche, Germany) according to the manufacturer's instructions. The
quantity and quality of the extracted RNA samples were confirmed by
optical density ratio of 260 nm–280 nm using NanoDrop 2000 instru-
ment (Wilmington, USA) and agarose gel analysis, respectively. For
reverse transcription polymerase chain reaction (RT-PCR), 400 ng of
total RNAwas reverse transcribed into First Strand cDNA complementary
DNA (cDNA) by cDNA synthesis kit (Fermentase, Germany) based on the
manufacturer's protocols. Finally, the cDNA samples were kept at -70 C
until used for PCR.2.3. PCR and real-time PCR analysis
The beta-actin gene was used as a housekeeping gene to normalize
expression of target genes. Oligo7 software (version 7.56) was used to
design the primers. To eliminate amplification of genomic DNA and
pseudogenes, primers were validated using Primer- BLAST online soft-
ware (Table 2). In all samples, a PCR reaction was performed to confirm
transcription of target genes and to determine the contamination of the
DNA using master mix PCR (Cinnagen, Tehran, Iran), specific gene
primers and cDNA. Then the samples were loaded on a 1.5% gel. Real-
time PCR was carried out for relative quantification of the mRNA
expression of all Targeted genes using SYBR Green Real-time PCR Master
Mix (Light Cycler Fast Start DNA Master Plus SYBR Green I, Roche,
Germany), previously Designed primers, and cDNA. Detection of fluo-
rescent intensity in each sample was accomplished using a Thermocycler
Rotor-Gene 6000 instrument (Corbett Research/Australia). Melting
curve analysis indicated only one peak per reaction that was further
confirmed by observing a band by electrophoresis of PCR products.Controls (n ¼ 30) Independent t-test (p-value)
15/15 -
82.5  5.1 p < 0.001
24.8  3.2 p < 0.0001
- -
- -
State Examination. Interpretation of the scores on the MMSE (out of 30 points)
oints) and normal cognition (24 or more points) [25].
Table 2. The primer data for 5-HTR2A, 5-HTR3A, MAO-A and β-actin.
Genes OligoName Primers Sequence (50→ 30) Amplicon Size (bp) Annealing Tm (⁰c) Genbank Accession Number
5-HTR2A 5HTR2A- F CCATCCAGAATCCCATCCACC 180 56 NM_001165947.2
5HTR2A-R GGACAAAGTTATCATCGGCGAG
5-HTR3A 5HTR3A-F GGTACCGGCAGTACTGGA 466 63 NM_001161772.3
5HTR3A- R CGGCGGATGACCACATAG
MAO-A MAO-A- F GCTGGACAAAGACTGCTAGGCGG 225 63 NM_000240.3
MAO-A- R GCTTCACTTGGTCTCCGAGGAGGT
ACTB β-actin- F AGACGCAGGATGGCATGGG 161 62 NM_001101.3
β-actin- R GAGACCTTCAACACCCCAGCC
5-HT2A, 5-hydroxytryptamine receptor 2A; 5-HTR3A, 5-hydroxytryptamine receptor 3A; MAO-A, Monoamine oxidase A; β-actin, Beta-actin.
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The LinRegPCR Software (Version 11.0) was used to calculate PCR
efficiency (E) and crossing point deviation (ΔCP) based on Real-time PCR
data of each sample. Subsequently, Relative Expression Software Tool
(REST © 2009, Version 2.0.13) was used for statistical analysis and the
calculation of relative gene expression. GraphPad Prism Software
(version 8.0.2.263; San Diego, CA) was used to determine the normal
distribution of variables using the Kolmogorov-Smirnov test. Compari-
sons have been calculated by SPSS software (version 23; IBM SPSS Sta-
tistics). To compare the mean of each group, independent t-test was used
and the Pearson correlation coefficient was used to determine the rela-
tionship between the variables. P-value of less than 0.05 was considered
statistically significant.3
3. Results
3.1. Comparison of demographic characteristics between LOAD and
control groups
Means and standard deviations for the age and MMSE total score in
both groups and age of disease onset and duration of illness in the LOAD
group are presented in Table 1. Based on these results, the majority of
patients in the LOAD group were in severe cognitive impairment, and the
majority of the control group were in normal cognitive status. To assess
the differences between the two groups in terms of age and MMSE score,
Levene's test for equality of variances was initially performed. In the age
variable, the statistical value of F¼ 0.731 and p-value¼ 0.396 and in the
MMSE score variable, the statistical value of F ¼ 0.449 and p-value ¼Figure 1. Comparison of fold changes in
mRNA expression levels of 5-HTR2A, 5-
HTR3A, and MAO-A in PBMCs samples
among control individuals and LOAD pa-
tients. A: 5-HTR2A is DOWN-regulated in
LOAD patients (in comparison to control in-
dividuals) by a mean factor of 0.376 (p ¼
0.0008). B: 5-HTR3A is DOWN-regulated in
LOAD patients (in comparison to control in-
dividuals) by a mean factor of 0.418 (p ¼
0.0046). C: MAO-A is DOWN-regulated in
LOAD patients (in comparison to control in-
dividuals) by a mean factor of 0.014 (p <
0.0001). D: The mRNA expression ratios
plotted for 5-HTR2A, 5-HTR3A, and MAO-A
were significantly decreased in LOAD pa-
tients in comparison to the control in-
dividuals. Error bars represent standard
Error of Mean. The number of subjects in
each group ¼ 30. Statistical significance is
denoted by an asterisk: **, P < 0.01; ***, P <
0.001; ****, P < 0.0001. PBMCs, Peripheral
Blood Mononuclear Cells; LOAD, Late-onset
Alzheimer's disease.
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tically significant difference in the Age and MMSE score variables be-
tween two groups (p < 0.001, p < 0.0001, respectively).
3.2. Comparisons of 5-HTR2A, 5-HTR3A, and MAO-A mRNA expression
between the two groups
Independent t-test showed that the relative level of 5-HTR2A, 5-
HTR3A, and MAO-A mRNA expression in PBMCs significantly decreased
in the LOAD group compared to the control group (p ¼ 0.0008, p ¼
0.0046, p < 0.0001, respectively).
The relative levels of 5-HTR2A, 5-HTR3A, and MAO-A mRNA
expression based on the log2-transformed value are shown in Figure 1.
3.3. Correlation analysis of 5HTR2A, 5HTR3A and MAO-A mRNA
expression with demographic characteristics
In the control group, the Pearson correlation test was performed be-
tween each of the variables age and MMSE total score with relative
expression of 5-HTR2A, 5-HTR3A and MAO-A genes, respectively. Ac-
cording to the obtained results, no statistically significant relationship
was observed between the mentioned variables.
4. Discussion
The results of this study showed a significant decrease in 5-HTR2A, 5-
HTR3A and MAO mRNA levels in PBMCs of patients with LOAD. We
suspect that a decrease in the expression of 5-HTR2A and 5-HTR3A
mRNA in PBMCs of patients with LOAD may reflect a decrease in their
brain levels. Since CNS tissues are generally not available for genetic
studies, the idea of replacing more accessible tissues such as peripheral
blood lymphocytes has been proposed. It has been shown that careful and
deliberate use of peripheral gene expression may be a useful alternative
to gene expression in the CNS, and the peripheral gene expression pattern
establishes a reasonable relationship with CNS gene expression, espe-
cially when identifying the respective genes in the target tissues [11].
5-HT receptors (5-HTRs) include seven classes from 5-HTR1 to 5-
HTR7, some of which have a variety of subclasses. The 5-HTR2A class,
along with the other 5 classes, are all G-protein-coupled receptors, while
the 5-HTR3A receptor is a ligand-gated ion channel receptor that regu-
lates permeability to sodium, potassium and calcium ions in the CNS and
peripheral nervous system [28, 29]. In the brain, 5-HT serves as a
neurotransmitter while in the periphery it serves as a hormone regulating
a range of processes. Because 5-HT does not transit the Blood-Brain
Barrier (BBB), peripheral and CNS 5-HT has no cross over, and func-
tionally can be considered to two distinct molecules [30].
5-HT is a component of the monoaminergic system that modulates
cognitive functions and some symptoms of AD are attributed to disorders
of the serotonergic system [31, 32]. Serotonergic neurons are composed
of a vast and complex network that is present in almost all brain struc-
tures [1] and as expected, extensive serotonergic denervation has long
been reported in the brain of patients with AD [33, 34, 35]. Aligned with
these findings, 5-HT depletion, as well as its metabolites, have been
observed in post-mortem AD brain tissue [36, 37, 38]. 5-HT receptors are
selectively affected in AD and the 5-HT2 receptor family is generally
defective [39, 40]. In support of this finding, Studies using various
methods such as immunohistochemistry, post-mortem, and imaging have
all shown a reduction in brain 5-HTR2A density in patients with AD [41,
42, 43, 44, 45, 46]. Moreover, reduction of 5-HTR2A in patients with
amnestic mild cognitive impairment is widespread and occurs early in
the course of the disease [47]. Based on the peripheral marker hypothesis
that suggests the expression level of neurotransmitter receptors in pe-
ripheral blood lymphocytes is parallel to the expression level in the brain
[48], our results also showed a decrease in 5-HTR2A gene expression in
PBMCs of patients with LOAD, which is consistent with the results of
previous similar studies on Alzheimer's brains. While the 5-HTR34
location in brain areas is related to the phenomenon of cognition, so far
few studies have been conducted on the involvement of 5-HT3 receptors
in cognitive functions, and most studies are limited to the effects of re-
ceptor antagonists on improving memory [49, 50, 51, 52].
In human peripheral blood, the immune cells express 5-HT receptors
of 5-HTR1, 5-HTR2, 5-HTR3, 5-HTR4, and 5-HTR7 classes and MAO. 5-
HTR2A and 5-HTR3A are expressed by monocytes, macrophages, and T
cells. Besides, 5-HTR2A is expressed by eosinophils, B cells, and platelets.
MAO is expressed by monocytes, macrophages, T cells, and platelets
[53]. One of the strongest evidence that immune cells respond to 5-HT is
that they essentially express the molecular machinery that makes up the
serotonergic system [54]. As mentioned earlier, some researchers have
identified AD as a systemic disease that can also affect peripheral tissues
outside the central nervous system [23, 55], and that peripheral and CNS
5-HT are not physiologically able to cross BBB [30], they somehow
complicate the role of 5-HT in the pathogenesis of AD. The presence of
5-HT receptors in both PBMCs and the nervous system indicates a
possible role for 5-HT in the relationship between the CNS and the im-
mune system [56]. One possible intermediate system in the human body
that can interact with both 5-HT and AD is the immune system. Our
possible assumption is that 5-HT affects the immune system, and the
altered immune system, in turn, keys the mechanisms for brain damage
and AD progression. This assumption is reinforced by recent studies
showing that 5-HT regulates a wide range of leukocyte functions, from
activating the immune response to the formation of immune memory
cells. Interestingly, 5-HT modulates cytokine secretion in mono-
cytes/macrophages, or it can suppress Tumor Necrosis Factor-α (TNF-α)
and interleukin-1 β (IL-1 β) by activating 5-HTR2A in PBMCs [54]. Other
researchers have shown that 5-HT in human monocytes modulates the
release of various cytokines and chemokines, mainly through 5-HTR3,
5-HTR4 and 5-HTR7 [57].
Growing studies have shown that in AD, the presence of persistent
and unresolved inflammation in neurons (Neuroinflammation) may lead
to the destruction of neurons and a decrease in functional and cognitive
abilities [58, 59, 60, 61, 62]. This inability to relieve inflammation in the
brains of AD patients, which results in the activation of microglial cells
and astrocytes, leads to the use of peripheral immune cells and the
overproduction of pro-inflammatory mediators [63, 64]. In the CNS,
activated microglial cells have been shown to release pro-inflammatory
cytokines, including IL-1 β, IL-6, and TNF-a, thereby leading to the
dendritic spine loss [65, 66]. As mentioned earlier, an increase in the
release of IL-1 β and TNF-a outside the CNS has also been observed in
response to the inactivation of 5-HTR2A in PBMCs [54]. Therefore, such
similar events could indicate possible links between the hormonal role of
5-HT in the peripheral and the neurotransmitter role of 5-HT in the CNS,
which requires further studies. Furthermore, changes in BBB in AD may
be an early and important step in pathogenesis [67]. Microglial priming
could sensitize the BBB to disruptive changes [68]. The cellular infil-
tration during systemic inflammation in AD is also associated with
several BBB changes without disturbance, which may increase amyloid
deposition and contribute to disease progression [69]. Because both
acute and chronic systemic inflammation can accelerate the progression
of AD [70], peripheral 5-HT may also be able to exert its regulatory ef-
fects on the brain, either through primary BBB changes or through sys-
temic inflammation that causes secondary BBB changes. However, more
research is needed to clarify these issues.
In a review of the literature, no similar studies of 5-HTR2A, 5-HTR3A
and MAO-A gene expression in PBMC of patients with LOAD were found,
but so far the peripheral expression profiles of each of these genes (alone
or in combination) have been investigated in other human disorders such
as depression, multiple sclerosis, breast cancer, and allergic asthma [56,
71, 72, 73, 74]. Although only one study using [3H]LSD as a radio-ligand
showed that platelet density of 5-HT2 receptors in AD patients was not
significantly different from that of healthy controls [75], no similar
studies were found to investigate the 5-HT receptors in other peripheral
blood cells of AD patients. Despite documented involvement of the
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standing of the molecular downstream mechanisms that explain the ef-
fects of each component of this system on AD [76].
MAO-A, which preferentially oxidizes 5-HT, is responsible for the
presynaptic degradation of 5-HT [77, 78]. Some studies have reported
both increased MAO-A activity and gene expression in different brain
regions of patients with AD [21, 79, 80]. Increased MAO activity will be
associated with a decrease in CNS monoamine levels such as 5-HT. A
change in the serotonergic system is observed in the aging brain, as well
as in depressed and aggressive patients with AD, and these changes may,
in turn, play an important role in memory decline and other cognitive
functions [81, 82, 83, 84, 85]. In the present study, a decreased MAO-A
gene expression was observed in PBMCs of patients with LOAD, which is
in contrast to previous findings on the activity of this enzyme in the brain
of patients with AD. This contradiction may be due to an unknown
compensatory mechanism in the brain versus the periphery and warrants
further studies.
As the decrease in the 5-HTR2A receptor has been reported in the
early stages of mild cognitive impairment [47], our argument for a
decrease in the expression of 5-HTR2A, 5-HTR3A and MAO mRNA in
PBMCs of patients with LOAD is that these changes may precede the
onset of AD. These genetic changes in the blood cells of patients may
coincide with the progression of AD in the CNS. These changes may occur
early and before pathological changes in the brain. Therefore, such
changes may be used as a clinical tool in the early diagnosis of AD before
overt mental deterioration.
The present study had several limitations. This study was limited to
mRNA analysis and did not include the evaluation of 5-HT receptor
subunit proteins. MAO activity was not measured. Larger sample sizes
with more diverse participants are also needed for generalizable results.
Research on peripheral blood gene expression is very promising, as it
would be economically and technically difficult to detect such changes
directly in vivo in the CNS. Conducting similar sets of studies in post
mortem tissue in which both peripheral and CNS samples are available
simultaneously, would be useful to further investigate the association
between 5-HTR2A, 5-HTR3A and MAO mRNA levels in the blood and
brain of AD patients.
5. Conclusion
The present study found that patients with LOAD have lower mRNA
expression levels of 5-HTR2A, 5-HTR3A, and MAO-A comparing with
their healthy counterparts. These genetic changes in the blood cells of
patients with LOAD can act as an affected tissue and coincide with the
progression of AD in the CNS, or even these changes occur early and
before any pathological changes in the brain tissue of these patients. Our
findings may help further clarify the link between serotonergic system
and the immune system that have been shown to be effective in the
pathogenesis of AD. However, if these molecular changes are influenced
by the tissue's response to AD-related pathologies, it possibly will provide
a new pathway for studies focused on blood-based markers that looking
for diagnostic or prognostic biomarkers in LOAD.
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